Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
12 DOSES OF UPTRAVI 1000 MCG TABLETS (GENERIC SELEXIPAG) FOR VA SAN DIEGO is a federal award for 262-Network Contract Office 22 (36C262) held by Actelion Pharmaceuticals Us Inc. Estimated value $172K ($172K obligated). Current period of performance ends Oct 5, 2023. Last award drew 1 bidder. Place of performance: LAKE MARY FL.
12 DOSES OF UPTRAVI 1000 MCG TABLETS (GENERIC SELEXIPAG) FOR VA SAN DIEGO
Recompete timing
PublicCurrent PoP ended Oct 5, 2023 (1092 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C26222F0620? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordActelion Pharmaceuticals Us Inc — $5.4M obligated across 106 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C26222F0620?
36C26222F0620 (12 DOSES of uptravi 1000 MCG) is a 262-Network Contract Office 22 (36C262) award with a potential value of $172K, currently held by Actelion Pharmaceuticals Us Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C262-22-F-0620?
36C262-22-F-0620 is the dashed form of PIID 36C26222F0620 (12 DOSES of uptravi 1000 MCG), held by Actelion Pharmaceuticals Us Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C26222F0620?
262-Network Contract Office 22 (36C262) awarded 36C26222F0620 to Actelion Pharmaceuticals Us Inc (potential $172K).
Who is the incumbent on 36C26222F0620?
Actelion Pharmaceuticals Us Inc is the incumbent with $5.4M across 106 related awards in SCOUT’s public footprint. The current period of performance ends Oct 5, 2023.
When does Actelion Pharmaceuticals Us Inc’s 36C26222F0620 come up for recompete?
SCOUT tracks a period-of-performance end of Oct 5, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C26222F0620? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.